BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
6/14/2017 9:25:57 AM | Browse: 947 | Download: 1354
 |
Received |
|
2016-12-29 10:26 |
|
Peer-Review Started |
|
2016-12-29 15:53 |
|
To Make the First Decision |
|
2017-02-10 08:45 |
|
Return for Revision |
|
2017-02-15 08:44 |
|
Revised |
|
2017-03-30 00:40 |
|
Second Decision |
|
2017-05-04 16:34 |
 |
Accepted by Journal Editor-in-Chief |
|
|
|
Accepted by Company Editor-in-Chief |
|
2017-05-09 17:08 |
|
Articles in Press |
|
2017-05-09 17:08 |
|
Publication Fee Transferred |
|
|
|
Edit the Manuscript by Language Editor |
|
|
|
Typeset the Manuscript |
|
2017-06-06 10:17 |
|
Publish the Manuscript Online |
|
2017-06-14 09:25 |
| ISSN |
1007-9327 (print) and 2219-2840 (online) |
| Open Access |
This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/ |
| Copyright |
© The Author(s) 2017. Published by Baishideng Publishing Group Inc. All rights reserved. |
| Article Reprints |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
|
| Permissions |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
|
| Publisher |
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA |
| Website |
http://www.wjgnet.com |
| Category |
Gastroenterology & Hepatology |
| Manuscript Type |
Basic Study |
| Article Title |
Serelaxin increases the antifibrotic action of rosiglitazone in a model of hepatic fibrosis
|
| Manuscript Source |
Invited Manuscript |
| All Author List |
Robert G Bennett, Ronda L Simpson and Frederick G Hamel |
| Funding Agency and Grant Number |
| Funding Agency |
Grant Number |
| The United States Department of Veterans Affairs Biomedical Laboratory Research and Development Program |
BX000849 |
| National Institutes of Health, NIAAA |
R01AA015509 |
|
| Corresponding Author |
Robert G Bennett, PhD, Professor, Department of Internal Medicine, University of Nebraska Medical Center, Omaha, NE 68198,
United States. rgbennet@unmc.edu |
| Key Words |
Relaxin; Peroxisome proliferator-activated receptors; Liver cirrhosis; Liver diseases; Fibrosis |
| Core Tip |
Hepatic fibrosis is a chronic condition that can lead to cirrhosis, but treatment options are limited and ineffective. Agonists of peroxisome proliferator-activated receptor gamma (PPARγ), such as rosiglitazone have shown limited efficacy. The hormone relaxin has antifibrotic effects, and increases the activity of PPARγ, leading to the hypothesis that combination treatment may be more effective. Mice with established hepatic fibrosis were treated with relaxin and rosiglitazone alone or in combination. Combination treatment reduced liver fibrosis, and increased the level of a PPARγ coactivator. These results suggest that relaxin and PPARγ co-therapy could be a more effective treatment for hepatic fibrosis. |
| Publish Date |
2017-06-14 09:25 |
| Citation |
Bennett RG, Simpson RL, Hamel FG. Serelaxin increases the antifibrotic action of rosiglitazone in a model of hepatic fibrosis. World J Gastroenterol 2017; 23(22): 3999-4006 |
| URL |
http://www.wjgnet.com/1007-9327/full/v23/i22/3999.htm |
| DOI |
http://dx.doi.org/10.3748/wjg.v23.i22.3999 |
© 2004-2024 Baishideng Publishing Group Inc. All rights reserved. 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
California Corporate Number: 3537345
